Biostatistics and Bioinformatics in Clinical Trials

Published on 04/03/2015 by admin

Filed under Hematology, Oncology and Palliative Medicine

Last modified 04/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 828 times

Chapter 19

Biostatistics and Bioinformatics in Clinical Trials

Summary of Key Points

• The process of conducting cancer research must change in the face of prohibitive costs and limited patient resources.

• Biostatistics has a tremendous impact on the level of science in cancer research, especially in the design and conducting of clinical trials.

• The Bayesian statistical approach to clinical trial design and conduct can be used to develop more efficient and effective cancer studies.

• Modern technology and advanced analytic methods are directing the focus of medical research to subsets of disease types and to future trials across different types of cancer.

• A consequence of the rapidly changing technology for generating “omics” data is that biological assays are often not stable long enough to discover and validate a model in a clinical trial.

• Bioinformaticians must use technology-specific data normalization procedures and rigorous statistical methods to account for sample collecting, batch effects, multiple testing, confounding covariates, and any other potential biases.

• Best practices in developing prediction models include public access to the information, rigorous validation of the model, and model lockdown prior to its use in patient care management.